iOnctura is a clinical-stage biotechnology company that specializes in developing treatments for cancer.
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 20, 2022 | Series Unknown | €15M | 1 | European Innovation Council | — | Detail |
Dec 20, 2022 | Grant | €2.50M | 1 | European Innovation Council | — | Detail |
Sep 22, 2022 | Debt Financing | Fr400K | 1 | FONGIT Innovation Fund | — | Detail |
Jul 14, 2020 | Series A | €5.10M | 5 | 3B Future Health Fund | — | Detail |
Jan 23, 2020 | Series A | €15M | 4 | Inkef VI Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Series Unknown |
FONGIT Innovation Fund | Yes | Debt Financing |
3B Future Health Fund | Yes | Series A |
Inkef | — | Series A |
M Ventures | — | Series A |
Schroder Adveq | — | Series A |
VI Partners | — | Series A |